(Photo By: Courtesy of Migal Galilee Research Team)
By: NoCamels Team - November 7, 2021
Israel’s MigVax, the affiliate company established by Israeli scientists at the Migal Galilee Research Institute to develop a vaccine for the coronavirus, has received a $4.3 million award from Norway’s Coalition of Epidemic Preparedness Innovations (CEPI) to help support the initial development of its COVID-19 oral subunit vaccine tablet.
The funding is part of a $200 million CEPI program to advance the development of vaccines that provide broad protection against variants of COVID-19 and other beta coronaviruses.
Canada’s University of Saskatchewan also received a CEPI funding award for its Vaccine and Infectious Disease Organization. The CEPI will support the researchers of these two institutions as they seek to establish preclinical proof of concept for novel vaccines suitable for use in low-and-middle-income countries that are broadly protective against COVID-19 variants, the CEPI announcement said.
Read More: NoCamels